Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.

Simulations Plus Inc.

Simulations Plus ( ($SLP) ) just unveiled an announcement. The news release from Simulations Plus does not provide specific details about the compa...

Simulations Plus Announces New Executive Appointments

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Pelthos Therapeutics (PTHS – Research Report) and Si...

Analysts Offer Insights on Healthcare Companies: Pelthos Therapeutics (PTHS) and Simulations Plus (SLP)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Simulations Plus (SLP – Research Report), Inotiv (NO...

Current Quarter	$0.19	Next Quarter	$0.24
Current Year	$1.04	Next Year	$1.2
QoQ Growth	+26.3%	YoY Growth	+15.4%
3Y EPS CAGR	+0.7%	Target Price	$23.00
Consensus	Buy	Upside	+20.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SLP	$19.17	-1.74%	232.30K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SLP	$19.17	-1.7%	232.30K
3
4
5
6

SLP

SLP

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Simulations Plus Inc. Data in Excel

Get Simulations Plus Inc. Data in Excel